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MYC dysregulation, includingMYC gene rearrangement and Myc protein overexpression, is of increasing clinical
importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of
rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated
with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in
lymphomagenesis. In this study, we determined MYC rearrangement status (n=344) and Myc expression
(n= 535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of
patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene
expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and
activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc
overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal
center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression
significantly contributed to the clinical, biological, and prognostic characteristics of the overall
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Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the
occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC
rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor
microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL
patients, even among MychighBcl-2high DLBCL patients. This study provides new insight into the tumor biology
and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC
translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL
patients.
Modern Pathology (2015) 28, 1555–1573; doi:10.1038/modpathol.2015.118; published online 6 November 2015
MYC is a proto-oncogene that encodes the Myc
protein, which is critical for cell proliferation, growth,
metabolism, differentiation, apoptosis, and immune
responses. In mouse models, Myc inactivation induces
sustained tumor regression via both tumor cell-
intrinsic and host-dependent mechanisms.1 The selec-
tive small-molecule bromodomain inhibitor JQ1 has a
potent antiproliferative effect that was associated with
the effective downregulation of MYC and Myc target
genes2 rendering this agent to have great therapeutic
potential.3
The chromosomal rearrangement or translocation
involving MYC and other genes (most commonly the
immunoglobulin heavy-chain gene (IGH) locus)
leads to Myc overexpression and occurs in ~ 10%
of diffuse large B-cell lymphomas (DLBCLs).4–8
DLBCL is the most common type of non-Hodgkin's
lymphoma, and among MYC-rearranged aggressive
lymphomas, DLBCL is the entity that clinicians most
commonly encounter.9,10 Several studies have
reported that MYC translocations independently
predicted significantly poor survival in DLBCL
patients.11–16 However, other studies found incon-
sistent results17–19 or limitations of its prognostic
significance.20,21
The clinical significance of Myc overexpression in
DLBCL has also been the source of much attention
and controversy. Several groups including ours have
found that DLBCL with high Myc protein expression
detected by immunohistochemistry had inferior
survival.5,13,22–24 Furthermore, the poor prognosis
associated with Myc overexpression was contributed
by cases with Myc/Bcl-2 coexpression—‘double-
positive lymphoma’ (DPL)—which account for 18–
44% of DLBCLs.13,20,23–26 However, one study
showed that the prognostic value of double-positive
lymphoma was lost in younger DLBCL patients with
poor prognosis.27 Inconsistent results have been
reported regarding whether the prognostic signifi-
cance of Myc or Myc/Bcl2 protein expression
depends on MYC or MYC/BCL2 gene rearrangement
status or not.8,13,20 Other issues include whether
Myc/Bcl2 immunohistochemistry is robust and
reproducible,28 and that immunohistochemistry cut-
off values have varied among different study
groups,13,20,23–26 which may affect the specificity of
this combined biomarker for poorer prognosis.
Possible molecular mechanisms underlying the
inconsistent clinical results may include presence or
absence of other genetic abnormalities and onco-
genic pathways,29–31 as well as another aspect of
Myc function: promoting apoptosis.32 Moreover,
researchers have recently reported findings that
Myc is a universal amplifier of 10–15% in human
genome, suggesting that Myc function is nonspecific
and that the consequences of MYC activities are
affected by pre-existing molecular programs in the
tumor cells.33,34 Therefore, tumor biology associated
with MYC/Myc (designated MYC herein) abnormal-
ities may have important roles in the observed
adverse prognosis.
Taken together, bothMYC gene rearrangement and
Myc protein overexpression have been correlated
with significantly adverse prognosis in DLBCL.
However, how much of these two biomarkers over-
lap and differ, how much their associated tumor
biology affects the prognostic effects, and whether
the MYC functional role is molecular context-
dependent are not very clear. In this study, we
compared the occurrence and clinicopathologic
features of patients stratified by MYC rearrangement
and Myc expression status, and analyzed the
differential prognosis and gene expression profiling
associated with these MYC abnormalities in a well-
characterized DLBCL cohort to assess the utility of
these two genetic and protein biomarkers and
explore the prognostic determinants. This study is




The study cohort consisted of 539 R-CHOP-treated
patients with de novo DLBCL from the International
DLBCL Rituximab-CHOP Consortium Program,
including 466 cases from the training set of a
previous study,24 and additional 73 cases with either
Myc immunohistochemistry or MYC gene rearrange-
ment status determined. The diagnostic criteria,
review process, and eligibility and exclusion criteria
have been described previously.35,36 The cell-of-
origin classification as either the germinal center
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B-cell-like (GCB) or activated B-cell-like (ABC)
subtype was determined using gene expression
profiling and/or immunohistochemistry for CD10,
BCL6, GCET-1, FOXP1, and MUM1 using the Visco-
Young and/or Choi algorithms as described
previously.24,35,36 Totally, 276 cases were classified
as GCB, 259 cases were classified as ABC, and 4
cases were unclassifiable. All patients underwent
standard R-CHOP or R-CHOP-like therapy, and the
median follow-up time was 45 months (range,
30–176.1 months). This study was conducted in
accordance with the Declaration of Helsinki and was
approved as being of minimal to no risk or as exempt
by the institutional review boards of all participating
centers, including The University of Texas MD
Anderson Cancer Center.
Fluorescence In Situ Hybridization,
Immunohistochemistry, and Gene Sequencing
MYC translocation was detected by fluorescence
in situ hybridization using two probes (a locus-
specific identifier IGH/MYC/CEP8 tri-color dual-
fusion probe and a locus-specific identifier MYC
dual-color break-apart probe) (n=344). Myc expres-
sion was assessed by immunohistochemistry using
tissue microarray sections and a monoclonal anti-(c)
MYC antibody, clone Y69 (Epitomics, Burlingame,
CA, USA) (n=535). The experimental techniques
and scoring processes have been described
previously.15,21,24
Evaluation of other biomarker expression by
immunohistochemistry was also performed on tissue
microarray sections using corresponding antibodies:
p53 (DO-7; Dako, Carpinteria, CA, USA), MDM2 (IF2;
Calbiochem, Billerica, MA, USA), Bcl-2 (Clone-124;
Dako), Ki-67 (MIB-1; Dako), pAKT (726E11; CST),
Bcl-6 (PG-B6p; DAKO), FOXP1 (EPR4113; Abcam),
MUM1/IRF4 (Dako), CD10 (56C6; Vantana), CD30
(clone BerH2; Dako), BLIMP-1 (EPR16655; Epi-
tomics), NF-κB subunits (Dako), CXCR4 (Abcam,
Cambridge, MA, USA), and survivin (EP2880Y;
Epitomics). BCL6 and BCL2 translocations and
TP53 mutations were detected as described
previously.15,21,24,35–42
Gene Expression Profiling
Gene expression profiling for 457 patients was
performed using the Affymetrix GeneChip Human
Genome HG-U133 Plus 2.0 Array as described
previously.21,24,35–37 The CEL files have been depos-
ited in the National Center for Biotechnology
Information Gene Expression Omnibus repository
(GSE31312). Microarray data were normalized for
further supervised clustering analysis. Multiple
t-tests were used to identify differentially expressed
genes and the P-values obtained were corrected for
the false discovery rate using the β-uniform mixture
method.
Statistical Analysis
The clinical and pathobiological features of DLBCL
patients at the time of presentation were compared
using the χ2 test. The mean expression levels of
biomarkers between DLBCL groups with or without
MYC abnormalities were also compared by unpaired
t-test. Overall survival (OS) was calculated from the
time of diagnosis to last follow-up or death from any
cause. Progression-free survival (PFS) was calculated
from the time of diagnosis to disease progression,
disease relapse, or death from any cause. Patients
who were alive and disease progression-free at last
follow-up were censored. Survival analysis was
performed using the Kaplan–Meier method with
the Prism 5 program (GraphPad Software, San Diego,
CA, USA), and differences in survival were com-
pared using the log-rank (Mantel–Cox) test. Multi-
variate survival analysis was performed using a Cox
proportional hazards regression model with the
SPSS software program (version 19.0; IBM Corpora-
tion, Armonk, NY, USA). All differences with
P≤ 0.05 were considered statistically significant.
Results
Myc Expression in Germinal Center B-Cell-Like and
Activated-B-Cell-Like Subtypes of DLBCL
We observed variable levels of nuclear Myc expres-
sion in DLBCL (n=535) (Figures 1a–c). The mean
expression level of Myc in ABC-DLBCL was signi-
ficantly higher compared with that in GCB-DLBCL
(Figure 1d). Among the cases successfully tested for
MYC rearrangement status (n=344), 27 (16.3%) of
166 GCB-DLBCL cases and 13 (7.3%) of 177 ABC-
DLBCL cases had MYC rearrangement/translocation.
Most but not allMYC-rearranged cases (MYC-R+) had
high MYC-mRNA and Myc expression, with an
average percentage of Mychigh nuclei in the tumor
samples of 70.5% (Supplementary Figure S1A). We
thus set the cutoff for Myc overexpression (Mychigh)
at ≥70%, so that Myc expression levels in MYC-
non-rearranged (MYC-R−) Mychigh patients compar-
ably ‘matched’ those in MYC-R+/Mychigh cases
(Supplementary Figure S1C) in comparisons of
clinical and biological significance of Myc over-
expression vs MYC translocation.
Using this cutoff, we found that 175 (32.7%) of 535
DLBCL patients, including 76 (27.9%) of 272 GCB-
DLBCL patients and 98 (37.8%) of 259 ABC-DLBCL
patients, were Mychigh (Figures 2a and b). Nineteen
(73%) of the 26 MYC-R+ GCB patients (one MYC-R+
GCB case had no expression data available) and 7
(54%) of the 13 MYC-R+ ABC patients were Mychigh,
who had significantly higher MYC transcripts and
significantly worse survival compared with the
MYC-R+/Myclow cases (Figures 1e–g and Supple-
mentary Figures S1D). Compared with MYC-R−
patients, MYC-R+/Mychigh patients had significantly
worse survival in GCB-DLBCL (P=0.0001 for OS and
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Po0.0001 for PFS) but not in ABC-DLBCL (P=0.56
for OS and P=0.14 for PFS) (Supplementary
Figures S1E and F). Comparison of MYC expression
levels between the MYC-R+ GCB, MYC-R− GCB,
MYC-R+ ABC, and MYC-R− ABC Mychigh groups
revealed that MYC-R+/Mychigh GCB-DLBCL had
significantly higher Myc protein expression levels
compared with all other subsets, and that among
both the GCB and ABC subtypes, MYC-R+/Mychigh
cases had a significantly higher level of MYC-mRNA
levels compared with MYC-R−/Mychigh cases
(Figures 2c and d).
Clinical Parameters Associated with Myc
Overexpression and MYC Rearrangement
We analyzed the clinical parameters associated with
Myc overexpression (Table 1) and MYC rearrange-
ment (Supplementary Table 1). We further compared
MYC-R+/Mychigh and MYC-R−/Mychigh cases
(Supplementary Table S2). Results of significant
characteristics are summarized in Supplementary
Table S3. Largely, both Myc overexpression and
MYC rearrangement could identify a subgroup of
patients with adverse clinical features in GCB-
DLBCL, whereas patients with these abnormalities
did not show such distinct characteristics among
ABC-DLBCLs.
For example, in GCB-DLBCL, Mychigh patients
compared with Myclow patients more often had stage
III/IV disease, ≥2 extranodal sites, ECOG performance
status ≥2, tumor size ≥5 cm, International Prognostic
Index 42, bone marrow involvement at clinical
presentation, and less likely to have complete
response. In ABC-DLBCL, Mychigh patients compared
with Myclow patients had a higher proportion of
women, and did not show significant association with
other clinical parameters. The GCB and ABC subtypes
of Mychigh patients differed significantly only in their
frequencies of patients with age ≥60 years (Table 1).
Similarly, in GCB-DLBCL, MYC-R+ patients were
enriched in patients with adverse clinical features,
whereas in ABC-DLBCL, MYC rearrangement
was only associated with primary extranodal origin.
The GCB subtype compared with the ABC subtype
of MYC-R+ patients showed trends toward having
a higher proportion of patients with bone marrow
involvement and non-complete treatment response
(Supplementary Table S1).
In both the GCB- and ABC-DLBCL groups,
MYC-R+/Mychigh patients appeared to have similar
clinical features with MYC-R−/Mychigh patients
(except complete response rate), yet may have
elevated serum lactate dehydrogenase levels
and higher frequency of extranodal origin
(Supplementary Table S2).
Months
in Diffuse Large B-cell Lymphoma in Germinal-center-B-cell-like
Diffuse Large B-cell Lymphoma
in Activated-B-cell-like













MYC-R+ GCB MYC-R+ ABC
In Diffuse Large B-cell Lymphoma
Figure 1 (a–c) Histograms of Myc expression according to immunohistochemistry staining in all diffuse large B-cell lymphoma (DLBCL)
patients, germinal center B-cell-like (GCB) DLBCL patients, and activated B-cell-like (ABC) DLBCL patients. (d) The mean Myc protein
levels of ABC-DLBCL were significantly higher compared with those of GCB-DLBCL. (e and f) MYC rearrangement-positive (MYC-R+)
DLBCL without high Myc immunohistochemistry scores (either GCB or ABC subtype) had significantly lower MYC-mRNA levels. (g)
MYC-R+ DLBCL patients without high Myc immunohistochemistry scores had significantly better overall survival compared with
MYC-R+/Mychigh DLBCL. Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
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Molecular Biomarkers Associated with Myc
Overexpression and MYC Rearrangement
Mychigh DLBCL compared with Myclow DLBCL, in
addition to having higher Myc levels and signifi-
cantly higher frequencies of MYC translocation and
ABC subtype (Table 1), had higher expression levels
of p53, MDM2, Bcl-2 (Mychigh ABC-DLBCL only),
Bcl-6, FOXP1, IRF4/MUM1 (Mychigh ABC-DLBCL
only), Ki-67, pAKT, CXCR4, and CD10 (Mychigh
GCB-DLBCL only), but lower expression levels of
BLIMP-1 (in ABC-DLBCL only) and nuclear expres-
sion of the NF-κB subunits c-Rel and RelB (in ABC-
DLBCL only, P=0.019, figure not shown) (Figure 3).
At the mRNA level, only MDM2 (in GCB-DLBCL
only), FOXP1 (in ABC-DLBCL only), IRF4 (in ABC-
DLBCL only), and MME/CD10 transcript levels
showed corresponding correlations consistent with
those at the protein level (Figures 4a–d). PRDM1
mRNA levels were significantly lower in Mychigh
GCB-DLBCL compared with that in Myclow GCB-
DLBCL (P=0.0005). The GCB and ABC subtypes of
Mychigh patients differed in frequencies of MYC
translocation, BCL2 translocation, TP53mutation (all
higher in the GCB subtype), and expression levels of
Bcl-2, p50, c-Rel (all higher in the ABC subtype),
pAKT (higher in the GCB subtype), and cell-of-
origin-related biomarkers (Bcl-6, BLIMP-1, GCET-1,
CD10, FOXP1, MUM1) (Table 1, Figure 3, and
Supplementary Table S3).
Some of the pathobiological associations with
Mychigh DLBCL were shared by MYC-R+ GCB-
DLBCL patients (compared with MYC-R− GCB-
DLBCL; Supplementary Tables S1 and S3). On the
other hand, in addition to the difference in Myc
activation mechanisms (MYC translocation or not),
MYC-R+/Mychigh compared with MYC-R−/Mychigh
patients had higher frequencies of GCB subtype
and BCL2 translocation, and lower frequencies of
BCL6 translocation, MUM1, CD30, and p52 expres-
sion (Supplementary Table S2 and S3). Among GCB-
DLBCL patients, MYC-R+/Mychigh compared with
MYC-R−/Mychigh patients had significantly higher
expression levels of MDM2, CD10, and FOXP1 but a
lower expression level of CD30; among ABC-DLBCL
patients, MYC-R+/Mychigh compared with MYC-R−/
Mychigh was associated with lower expression levels
of Bcl-6 and pAKT (Figures 4f–l).
GCB-DLBCL
Mychigh (27.9%) MYC-R+ 
(16.3%) Myclow (72%) 
ABC-DLBCL
Mychigh (37.8%) MYC-R+ 
(7.3%) Myclow (62.2%) 




Figure 2 Occurrence of MYC rearrangement (MYC-R) and overexpression (Mychigh) and MYC expression levels in diffuse large B-cell
lymphoma (DLBCL). (a and b) Schematic diagrams showing the frequencies of MYC translocation (MYC-R+) and Myc overexpression
(Mychigh) and their overlaps in germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL in the current study cohort. (c and
d) Comparisons of Myc protein andMYC-mRNA expression levels in DLBCL patients with or withoutMYC dysregulation. Among Mychigh
groups, MYC-R+ GCB-DLBCL had highest Myc protein levels; MYC-R+ DLBCL (both GCB and ABC subtypes) had significantly higher
MYC-mRNA levels compared with MYC-R− DLBCL. Note: Each dot represents one patient in the study cohort. MYC-R+, MYC
rearrangement-positive; MYC-R−, MYC rearrangement-negative; Mychigh, high Myc protein expression/Myc overexpressing; Myclow, low
Myc protein expression; MYC-RN/A, MYC rearrangement status not available.
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P3 values P4 values
Mychigh Myclow Mychigh Myclow Mychigh Myclow
N (%) N (%) N (%) N (%) N (%) N (%)
Variables 175 (100) 360 (100) 76 (100) 196 (100) 98 (100) 161 (100) 0.016
Age (years)
o60 73 (41.7) 150 (41.7) 1.0 42 (55.3) 91 (46.4) 0.22 30 (30.6) 57 (35.4) 0.50 0.0012
≥60 102 (58.3) 210 (58.3) 34 (44.7) 105 (53.6) 68 (69.4) 104 (64.6)
Gender
Female 78 (44.6) 146 (40.6) 0.38 30 (39.5) 85 (43.4) 0.56 48 (49.0) 59 (36.6) 0.05 0.21
Male 97 (55.4) 214 (59.4) 46 (60.5) 111 (56.6) 50 (51.0) 102 (63.4)
Stage
I and II 64 (37.9) 179 (51.3) 0.0041 31 (41.9) 110 (58.5) 0.015 32 (34.0) 68 (43.0) 0.16 0.30
III and IV 105 (62.1) 170 (48.7) 43 (58.1) 78 (41.5) 62 (66.0) 90 (57.0)
B-symptoms
No 103 (62.4) 227 (66.2) 0.41 45 (63.4) 133 (71.9) 0.19 58 (62.4) 91 (58.7) 0.57 0.89
Yes 62 (37.6) 116 (33.8) 26 (36.6) 52 (28.1) 35 (37.6) 64 (41.3)
LDH level
Normal 58 (35.4) 137 (41.6) 0.18 24 (34.3) 82 (46.1) 0.091 34 (36.6) 54 (36.5) 0.099 0.76
Elevated 106 (64.6) 192 (58.4) 46 (65.7) 96 (53.9) 59 (63.4) 94 (63.5)
Number of extranodal sites
0–1 117 (69.6) 279 (80.9) 0.0045 45 (63.4) 156 (83.9) 0.0004 67 (69.8) 120 (76.9) 0.21 0.38
≥2 51 (30.4) 66 (19.1) 26 (36.6) 30 (16.1) 29 (30.2) 36 (23.1)
ECOG performance status score
0–1 126 (77.3) 275 (86.8) 0.0082 53 (76.8) 150 (89.3) 0.013 72 (77.4) 122 (83.6) 0.24 0.93
≥2 37 (22.7) 42 (13.2) 16 (23.2) 18 (10.7) 21 (22.6) 24 (16.4)
Size of largest tumor (cm)
o5 64 (48.5) 170 (63.7) 0.0038 26 (47.3) 94 (64.4) 0.028 38 (49.4) 74 (62.2) 0.076 0.81
≥5 68 (51.5) 97 (36.3) 29 (52.7) 52 (35.6) 39 (50.6) 45 (37.8)
IPI score
0–2 88 (51.5) 234 (67.4) 0.0004 39 (52.7) 139 (74.3) 0.0007 47 (49.0) 92 (58.6) 0.13 0.63
3–5 83 (48.5) 113 (32.6) 35 (47.3) 48 (25.7) 49 (51.0) 65 (41.4)
Therapy response
CR 117 (66.9) 285 (79.2) 0.002 46 (60.5) 155 (79.1) 0.0018 70 (71.4) 127 (78.9) 0.17 0.13
PR 33 38 24 22 21 16
SD 9 15 5 10 4 5
PD 16 22 1 9 3 13
Primary origin
LN DLBCL 111 (63.8) 227 (63.9) 0.97 47 (63.5) 125 (64.8) 0.85 61 (63.5) 100 (62.9) 0.92 1.00
EN DLBCL 63 (36.2) 128 (36.1) 27 (36.5) 68 (35.2) 35 (36.5) 59 (37.1)
Bone marrow involvement
No 130 (83.9) 287 (92.6) 0.0036 52 (81.3) 163 (95.3) 0.0006 77 (85.6) 122 (89.1) 0.43 0.48
Yes 25 (16.1) 23 (7.4) 12 (18.8) 8 (4.7) 13 (14.4) 15 (10.9)
Ki-67 index (%)
o70 40 (22.9) 149 (42.2) o0.0001 24 (31.6) 83 (43.2) 0.097 16 (16.3) 65 (40.6) o0.0001 0.028
≥70 135 (77.1) 204 (57.8) 52 (68.4) 109 (56.8) 82 (83.7) 95 (59.4)
TP53 mutations
No 114 (74.5) 252 (78.8) 0.35 43 (65.2) 131 (75.7) 0.10 71 (81.6) 118 (81.9) 0.95 0.02
Yes 39 (25.5) 68 (21.3) 23 (34.8) 42 (24.3) 16 (18.4) 26 (18.1)
MYC translocation
No 81 (75.7) 220 (94.4) o0.0001 23 (54.8) 113 (94.2) o0.0001 58 (89.2) 106 (94.6) 0.23 o0.0001
Yes 26 (24.3) 13 (5.6) 19 (45.2) 7 (5.8) 7 (10.8) 6 (5.4)
BCL2 translocation
No 121 (86.4) 230 (79.9) 0.11 38 (67.9) 106 (67.9) 1.00 83 (98.8) 123 (93.9) 0.09 o0.0001
Yes 19 (13.6) 58 (20.1) 18 (32.1) 50 (32.1) 1 (1.2) 8 (6.1)
BCL6 translocation
No 77 (64.2) 169 (68.7) 0.38 37 (71.2) 103 (75.7) 0.52 39 (58.2) 65 (59.6) 0.85 0.14
Yes 43 (35.8) 77 (31.3) 15 (28.8) 33 (24.3) 28 (41.8) 44 (40.4)
Bcl-2 expression
o70% 76 (43.7) 195 (55.7) 0.012 40 (53.3) 121 (63.4) 0.16 35 (35.7) 73 (46.2) 0.12 0.03
≥70% 98 (56.3) 155 (44.3) 35 (46.7) 70 (36.6) 63 (64.3) 85 (53.8)
Abbreviations: ABC, activated-B-cell-like; CR, complete response; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology
Group; EN, extranodal; GCB, germinal-center-B-cell-like; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LN, lymph node;
Mychigh, high Myc protein expression; Myclow, low Myc protein expression; PD, progressive disease; PR, partial response; SD, stable disease.
Note: P-values indicate the significance of differences in the positivity frequencies of the listed parameters between two groups. P1 values are for
comparisons between overall Mychigh and Myclow DLBCL patients; P2 values are for comparisons between Mychigh and Myclow GCB-DLBCL
patients; P3 values are for comparisons between Mychigh and Myclow ABC-DLBCL patients; and P4 values are for comparisons between Mychigh
GCB-DLBCL and Mychigh ABC-DLBCL patients. For therapy response, we calculated P-values for differences between CR and other responses.
aWith high or low Myc expression levels (Mychigh vs Myclow) in the overall, GCB, and ABC cohorts. Bold values are statistically significant.
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Prognostic Effect of Myc Overexpression with or
without MYC Translocations and Associated Gene
Expression Profiling Signatures
We combined the survival analysis with gene
expression profiling comparisons to assess the role
of MYC abnormalities in DLBCL and to study
potential mechanisms. As in earlier studies,13,22–24
in the present study, high expression levels of Myc
was associated with significantly worse OS and PFS
in both GCB- and ABC-DLBCL (Supplementary
Figure S2). Similar prognostic impact was also
shown by high MYC-mRNA levels in GCB- and
ABC-DLBCL (Supplementary Figures S3A–D). Gene
expression profiling analysis showed that Mychigh
GCB- and ABC-DLBCL had different gene expression
profiling signatures (Table 2, Supplementary Figures
S2D and F, and Supplementary Table S4A). The
significantly differentially expressed genes between
these two groups included CDCA7L, IGF2BP3, and
RUVBL2, which are known to have roles in the
oncogenic transformation by MYC or to interact
with MYC.
MYC rearrangement did not show prognostic
significance in the Myclow cases [for OS: P=0.25
(OS of MYC-R+/Myclow patients was slightly better
than MYC-R−/Myclow DLBCL); for PFS: P=0.71].
Dividing the Mychigh cases with unfavorable prog-
nosis intoMYC-R+/Mychigh andMYC-R−/Mychigh two
types and comparing their prognosis and gene
expression profiling features, we further found that
MYC-R+/Mychigh GCB-DLBCL and MYC-R−/Mychigh
ABC-DLBCL were the main contributors to the
overall worse prognosis and distinct gene expression
profiling signatures of the Mychigh GCB-DLBCL and
Mychigh ABC-DLBCL groups, respectively.
In the GCB-DLBCL group, MYC-R+/Mychigh
patients had significantly worse survival than both
Myclow and MYC-R−/Mychigh patients did. Although
MYC-R−/Mychigh GCB-DLBCL showed trends
towards worse survival compared with the overall
Myclow GCB-DLBCL (P=0.40 for OS, Figure 5a;
P=0.48 for PFS; Supplementary Figure S4A), and
the MYC-R−/Myclow GCB-DLBCL (for OS: P=0.32;
Supplementary Figure S4C; for PFS: P=0.21),
the differences were not significant. Biologically,
only MYC-R+/Mychigh (but not MYC-R−/Mychigh)
GCB-DLBCL compared with Myclow GCB-DLBCL
showed a distinct gene expression profiling signa-
ture (false discovery rate o0.01) (Figure 5b,
Supplementary Table S4B, and Table 3), and this
signature mostly overlapped the Mychigh gene
expression profiling signature identified in the over-
all GCB-DLBCL group (Table 2 and Supplementary
Figure S2D) involving cell proliferation, gene expres-
sion, metabolism, apoptosis, microenvironment and
immune response, and microRNA genes. In contrast,
the MYC-R−/Mychigh GCB-DLBCL patients compared
with Myclow GCB-DLBCL (Supplementary Figures
S4D, Table 3, and Supplementary Table S4B) or
MYC-R+/Mychigh GCB-DLBCL (Figure 5c, Table 3,
and Supplementary Table S4B) only showed a few
differentially expressed genes below false discovery
rate threshold of 0.30 (not including MYC), most of
which are involved in cell proliferation, gene
expression, ribosome biogenesis, and metabolism,
suggesting the presence of heterogeneity and post-
transcriptional regulation of MYC as a cause of Myc
overexpression within the MYC-R−/Mychigh GCB-
DLBCL group. The comparison between MYC-R+
GCB-DLBCL and MYC-R− GCB-DLBCL overall is
shown in Supplementary Figure S4E.
In contrast, in ABC-DLBCL, the prognostic signi-
ficance (Figure 5d) and gene expression profiling
features of Myc overexpression did not depend on
MYC translocation. MYC-R−/Mychigh ABC-DLBCL
had significantly poorer survival compared with
the overall Myclow or MYC-R−/Myclow ABC-DLBCL
(Figure 5d and Supplementary Figures S4G–I) and
distinct gene expression profiling signatures (false
discovery rate o0.01; Figure 5e and Supplementary
Table S4C). The genes in the MYC-R−/Mychigh ABC-
DLBCL gene expression profiling signature, over-
lapped with differentially expressed genes between
the overall Mychigh vs Myclow ABC-DLBCL patients,
included typical Myc targets mainly related to
cell proliferation, the cell cycle, gene expression,
ribosome biogenesis, metabolism (Table 4), and
cooperating oncogenes such as RUVBL2, as well as
IGF2BP3 involved in post-transcriptional regulation
of MYC, and HINT1 modulating p53 levels and
the p53 pathway. Different from theMYC-R−/Mychigh
ABC-DLBCL cases, MYC-R+/Mychigh ABC-DLBCL
compared with overall Myclow ABC-DLBCL only
showed nonsignificant trends towards worse OS and
PFS (Figure 5d and Supplementary Figures S4G–I)
and only a few differentially expressed genes (false
discovery rate o0.30, Supplementary Figure S4F).
No genes were found differentially expressed
between MYC-R+/Mychigh ABC-DLBCL and MYC-R
−/Mychigh ABC-DLBCL, or between MYC-R+/Mychigh
ABC-DLBCL and the overall MYC-R− ABC-DLBCL
group. This is in contrast with the distinct gene
expression profiling feature of MYC-R+/Mychigh
GCB-DLBCL shown in Figure 5b and Supple-
mentary Figures S4E. Comparison between overall
MYC-R+/Mychigh ABC-DLBCL and MYC-R+/Mychigh
GCB-DLBCL indicated their different and potentially
heterogeneous tumor biology (Figure 5f) (between
MYC-R+/Mychigh and MYC-R+/Myclow GCB-DLBCL,
or between MYC-R+/Mychigh and MYC-R+/Myclow
ABC-DLBCL, we did not find significant dif-
ferentially expressed genes below false dis-
covery rate thresholds of 0.05–0.50). MYC-R+ ABC-
DLBCL appears to have decreased B-cell receptor
signaling compared with MYC-R+ GCB-DLBCL (false
discovery rate o0.30; Table 4 and Supplementary
Table S4C). However, the ‘loss’ of the gene expres-
sion profiling signature may also be due to the small
case number.
Comparing between GCB and ABC subtypes of
Mychigh patients, the overall GCB and ABC subtypes
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of Mychigh patients showed no significant difference
in survival (ABC subtype showed nonsignificant
trends towards poorer survival; Supplementary
Figures S3E and F). However, MYC-R+/Mychigh
GCB-DLBCL showed unfavorable trends compared
with Mychigh ABC-DLBCL (either MYC-R− or
MYC-R+). The P-value for the difference in PFS
between the MYC-R+/Mychigh GCB-DLBCL and
MYC-R−/Mychigh ABC-DLBCL patients was 0.058
(Figure 5g). MYC-R+/Mychigh GCB-DLBCL compared
with MYC-R−/Mychigh ABC-DLBCL or Myclow ABC-
DLBCL showed distinct gene expression profiling
signatures overlapping with the one comparing with
MYC-R− GCB-DLBCL. Comparisons between MYC-R+
DLBCL and MYC-R− DLBCL overall (regardless of
Mychigh orMyclow, GCB or ABC), and betweenMYC-R+/
Mychigh DLBCL overall and MYC-R−/Mychigh DLBCL
overall (regardless of GCB or ABC) are shown in
Figures 5h and i (Table 5 and Supplementary Table
S4D). These analyses suggest the distinctive biology of
MYC-R+/Mychigh GCB-DLBCL and cell of origin during
lymphomagenesis may have a role in defining its
biological feature.
Concurrent Evaluation of Myc/Bcl-2 Overexpression
and MYC Translocations
We examined whether the prognostic value of Myc
overexpression is contributed by or depends on the
molecular marker associations with Mychigh DLBCL
as shown in Figure 3. As shown previously, the
prognostic significance of Mychigh and Bcl-2high in
DLBCL significantly depend on each other.13,20,23–26
In addition, to a certain extent, the prognostic
significance of Mychigh showed dependence on
CXCR4,40 FOXP1, and MUM1 overexpression,
which are also associated with Bcl-2 overexpression
(the association of MUM1 was only in ABC but
not in GCB), high Ki-67 (for OS but not for PFS),
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P<0.0001 P=0.0002 P<0.0001 P<0.0001
P=0.012 P=0.01 P=0.013 P=0.85
Figure 3 Expression of pathobiological markers in germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell
lymphoma with or without Myc overexpression. In both GCB- and ABC-DLBCL, Myc overexpression was associated with significantly
higher levels of p53 (a), MDM2 (b), Ki-67 (d), Bcl-6 (f), and FOXP1 (g), and a significantly lower level of c-Rel (k). In GCB-DLBCL only, Myc
overexpression was associated with significantly higher levels of CD10 (e), pAKT (j), and CXCR4 (l). In ABC-DLBCL only, Myc
overexpression was associated with significantly higher levels of Bcl-2 (c) and MUM1 (h) levels and a significantly lower level of BLIMP-1
(i). Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
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Figure 4 (a–d) Myc overexpression was correlated with significantly higher levels of MDM2, IRF4, and MME/CD10 mRNA expression in
germinal center B-cell-like (GCB) diffuse large B-cell lymphoma and significantly higher levels of FOXP1 and IRF4 mRNA expression in
activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). (e) The MYC-R+/Mychigh compared with MYC-R−/Mychigh group had
significantly lower levels of MUM1 expression. (f–j) The MDM2, CD30, CD10, and FOXP1 levels in Mychigh GCB-DLBCL patients with
MYC translocation were significantly different from those of Mychigh GCB-DLBCL patients withoutMYC translocation. (k and l) The Bcl-6
and pAKT levels of Mychigh ABC-DLBCL patients with MYC translocation were significantly lower compared with those of Mychigh ABC-
DLBCL patients without MYC translocation. Mychigh, high Myc protein expression; Myclow, low Myc protein expression; MYC-R+, MYC
rearrangement-positive; MYC-R−, MYC rearrangement-negative; MYC-RN/A, MYC rearrangement status not available.
Table 2 Gene expression profile signatures of Myc protein overexpression in DLBCL, GCB-DLBCL, and ABC-DLBCL
DLBCL GCB-DLBCL ABC-DLBCL
Mychigh vs Myclow (false discovery
rate o0.05, fold change 41.53)
Mychigh vs Myclow (false discovery rate
o0.01, fold change 41.68)
Mychigh vs Myclow (false discovery
rate o0.01, fold change 41.31)
Upregulated MYC, AICDA, SNHG1, SNHG4,






MYC, PEG10, SNHG4, STRBP, CYP39A1,
DKFZp686O24166, PAICS, FAM72A/B/
C/D, CDC25A, SLC16A1, RPS21, DEPDC1,
HSPD1
MYC, MAD2L1, EEF1E1, RUVBL2,
SNHG1, RG9MTD1, MRPL3, IPO7,
CCDC86, TFAM, GAR1, MATR3,
SNHG4, TOMM5, NOC3L, WDR43,
DDX21, LYAR, RPL24, LOC388796,
SNHG8, WDR75, DCTPP1, MAT2A,
QDPR, APEX1
Downregulated CD3E, HOPX, TRBC1, COL3A1,
RGS1, COL3A1, TRBC1, ITM2A,
GZMK, ITGB5, ITM2A
MIR155HG, TRBC1, GABBR1/UBD, CD58,
CD3E, BHLHE41, GZMK, DUSP4, TRBC1,
SLAMF7, LCP2, RGS1, ITM2A, SKI,
SLAMF8, CD44, LOC285628, FYB, CCL5,
MDFIC, CCND2, BCL11B, TNFAIP3, SLFN5,
SNX9, IL10RA, GBP2
Abbreviations: ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; Mychigh, high Myc protein
expression; Myclow, low Myc protein expression.
Note: Genes are listed by the order of fold change (high to low).
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The lack of prognostic significance of Myc
overexpression without MYC translocation in GCB-
DLBCL (Figure 5a) could be attributable to
the favorable prognosis of Mychigh/Bcl-2low GCB-
DLBCL patients (Figures 6a and b and Supple-
mentary Figures S6A and B). In contrast, in the
ABC-DLBCL group, most MYC-R−/Mychigh patients
(64%) also had Bcl-2 overexpression, which con-
tributed to this group’s worse survival. Concurrent
Bcl-2 overexpression also had significant prognostic
impact in MYC-R+/Mychigh GCB-DLBCL (Figures 6c
and d), but not in overall MYC-R+ ABC-DLBCL,
MYC-R+/Mychigh ABC-DLBCL, or MYC-R+/Myclow
cases (Supplementary Figures S6C and D); however,
we could not distinguish whether the synergy in
GCB is with Bcl-2 protein or with BCL2 transloca-
tion. Compared with Myclow, MYC-R−/Mychigh GCB-
DLBCL, or overall MYC-R− GCB-DLBCL, MYC-R+/
Mychigh GCB-DLBCL showed nonsignificant trends
toward higher Bcl-2 levels (P=0.34, 0.27, and
P=0.17, respectively; figures not shown; Supple-
mentary Tables S1 and 2). The gene expression
profiling analysis revealed no significant differen-




Figure 5 Combined prognostic and biologic analysis of germinal-center-B-cell-like (GCB) and activated-B-cell-like (ABC) diffuse large
B-cell lymphoma (DLBCL) with or without MYC translocation (MYC-R) and/or Myc overexpression (Mychigh) in the current study cohort.
(a) GCB-DLBCL patients with bothMYC translocation and Myc overexpression (MYC-R+/Mychigh) had significantly worse overall survival
compared with GCB-DLBCL patients with low Myc expression (Myclow) and Mychigh patients without MYC translocation (MYC-R−/
Mychigh). The MYC-R−/Mychigh group did not have significant poorer survival compared with the Myclow group. (b) Genes significantly
differentially expressed betweenMYC-R+/Mychigh GCB-DLBCL patients and Myclow GCB-DLBCL patients (false discovery rate o0.01, fold
change42.38). (c) Genes significantly differentially expressed betweenMYC-R+/Mychigh andMYC-R−/Mychigh GCB-DLBCL patients (false
discovery rate o0.30). (d) Only MYC-R−/Mychigh but not MYC-R+/Mychigh ABC-DLBCL patients had significantly OS compared with
Myclow ABC-DLBCL patients. (e) Genes significantly differentially expressed between MYC-R−/Mychigh ABC-DLBCL and Myclow ABC-
DLBCL (false discovery rate o0.01, fold change41.57). (f) Genes significantly differentially expressed between ABC and GCB subtypes of
MYC-R+ DLBCL. (g)MYC-R+/Mychigh GCB-DLBCL showed trend towards worse progression-free survival compared withMYC-R−/Mychigh
ABC-DLBCL patients with a borderline P-value. (h) Genes significantly differentially expressed between MYC-R+ and MYC-R−DLBCL
(false discovery rate o0.01, fold change 41.66). (i) Genes significantly differentially expressed between MYC-R+/Mychigh and
MYC-R−/Mychigh DLBCL (false discovery rate o0.01, fold change 42.05). ABC, activated-B-cell-like; GCB, germinal-center-B-cell-like;
Mychigh, high Myc protein expression; Myclow, low Myc protein expression; MYC-R+: MYC rearrangement-positive; MYC-R−, MYC
rearrangement-negative.
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Table 3 Gene expression profile signatures of Myc protein overexpression in GCB-DLBCL
Functional categories Upregulated Downregulated
1. MYC-R+/Mychigh vs Myclow GCB-DLBCL (false discovery rate o0.01, fold change 42.38)
Signaling TRAF1, DUSP4, GABBR1/
UBD
Cell proliferation and growth, gene expression MYC, SMAD1, BACH2, STRBP FAM129A
Metabolism NNMT
Cell death PEG10, ZNF385B BCL2A1, TMEM49
Immune response, anti-viral/anti-microbial activities IGJ, DKFZp686O24166/ NCR3LG1 CD58, GBP1, SLAMF7, LYZ
Cell adhesion, extracellular matrix, migration FN1, BGN, CD44
microRNAs MIR21, MIR155HG
Unknown function TPD52
2. MYC-R−/ Mychigh vs Myclow GCB-DLBCL (false discovery rate o0.30, fold change 41.2)
Signaling RGS8, GPS1, FAM123A, PDLIM7
Cell proliferation and growth, gene expression,
ribosome biogenesis
C9orf100, SMARCA4, ZNF8, MRPS12,
EMG1, INTS1
Metabolism SLC25A27, FADS2, ACAD9
Microtubules, migration, cell interaction TUBB2C, TUBB3 LGALS8
Transport ABCA4, CHCHD4 VPS36
Long noncoding RNA, RNA gene NAPSB LOC202181, LOC440944
3. MYC-R+/Mychigh vs MYC-R−/Mychigh GCB-DLBCL (false discovery rate o0.30, fold change 41.3)
Signaling SIKE1 SPRED1
Transcription, ribosome biogenesis NAF1, RRP1B, SMAD1 FOXN3, ATN1
Metabolism GANC
Extracellular matrix, migration, cytoskeleton BGN, TRIOBP
Unknown function PWWP2A KIAA0913
Abbreviations: DLBCL, diffuse large B-cell lymphoma; GCB, germinal-center-B-cell-like; MYC-R+, MYC rearrangement-positive; MYC-R−, MYC
rearrangement-negative; Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
Table 4 Gene expression profile signatures of Myc overexpression in ABC-DLBCL
Functional categories Upregulated Downregulated
1. MYC-R− / Mychigh vs Myclow ABC-DLBCL (false discovery rate o0.01, fold change 41.57)
Cell proliferation, cell cycle, gene
expression, ribosome biogenesis
MYC, IGF2BP3, FOXP1, CCNB1, CKS2, DCAF13, THOC4, DDX11,
RUVBL2, RPS15, RPLP0, RPL35, RPL27A, RPLP2, RPSA, RPS21,
RPLP1, RPL15, PABPC1, DNAJC2, MAD2L1
Metabolism GRHPR, CYB5R2, ESD, TMEM97
DNA damage response EEF1E1, HINT1
Transport CSE1L, IPO5
RNA gene; unknown function SNHG1, LOC100291837
2. MYC-R+/ Mychigh vs Myclow ABC-DLBCL (false discovery rate o0.30, fold change 41.43)
Cell cycle, gene expression, ribosome
biogenesis
MYC, RPL24, NAF1, EIF4B, CCNT1, RPL29, ZNF485
Metabolism GART, PLA2G12A, MDH1B
Proteasome degradation, transport STUB1, NXT2
Pseudogene RPS10P5
3. MYC-R+ ABC-DLBCL vs MYC-R+ GCB-DLBCL (false discovery rate o0.15, fold change 41.3)
Signaling TNFRSF13B, SERPINA1, SH3BP5, TNIP3, ENTPD1, P2RY10,
CNPY3, PGAP2
STAP1, MME




IQGAP2, ARPC5, TMSB10, ACTA2, PARVB MARCKSL1
Immune response LILRB1/2, CD47 CAMP
Transport, degradation NXT2, EXOC4, PTPN1
Unknown function GRAMD1B, PHACTR2 C8orf6, TPD52
Abbreviations: ABC, activated-B-cell-like; DLBCL, diffuse large B-cell lymphoma; MYC-R+, MYC rearrangement-positive; MYC-R−, MYC
rearrangement-negative; Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
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with Bcl-2 expression and MYC-R+ GCB-DLBCL
without Bcl-2 expression. Correspondingly, patients
with MYC/BCL2 double-hit lymphoma and those
with single MYC rearrangements did not have
significant differentially expressed genes, which is
consistent with an earlier study.16 The survival of
MYC-R+ Mychigh/Bcl-2high GCB-DLBCL patients was
markedly poorer compared with that of MYC-R−
Mychigh/Bcl-2high GCB-DLBCL patients but this
difference was not significant (Figures 6e and f).
However, this difference was significant when
we used cutoffs of ≥ 40% or 450% for Myc
overexpression.
Although concurrent evaluation of Myc and Bcl-2
expression improves the specificity of Myc biomar-
ker in DLBCL, MYC rearrangement continues to
demonstrate clinical value. In our cohort, there was
no significant difference in survival between patients
with the GCB or ABC subtypes of MYC-R− Mychigh/
Bcl-2high (ie, double-positive lymphoma). Among
overall double-positive lymphoma patients, patients
with MYC-R+ GCB double-positive lymphoma
patients had significantly poorer survival compared
with those double-positive lymphoma patients with-
out MYC rearrangement (Figures 6g and h). The
survival of MYC-R+ double-positive lymphoma
patients with the GCB or ABC subtypes appeared to
be different, although P-values were not significant
and the case numbers were small.
Discussion
Previously, we reported MYC translocation and
Myc overexpression as adverse prognostic biomarkers
individually.15,24 In this study, we analyzed the
occurrence of MYC translocation and Myc over-
expression in GCB- and ABC-DLBCL (Figures 2a and
b), and compared with the clinical features and tumor
biology associated with these two overlapping bio-
markers which have not been done by previous
studies, and examined the dependence/independence
between their indicated prognoses. To reduce the
difference in Myc expression levels as a causing factor
for the differential prognostic effect and tumor biology
between MYC translocation and Myc overexpression
activated by other mechanisms, the cutoff for Mychigh
was set at ≥70% in this study, which is the optimal
cutoff for predicting MYC translocation according to
previous studies.6,7,31 Using this cutoff, the frequency
Table 5 Gene expression profile signatures of MYC-R+ GCB-DLBCL and MYC-R+ DLBCL overall
Functional categories Upregulated Downregulated
1. All (Mychigh or Myclow) MYC-R+ GCB vs all (Mychigh or Myclow) MYC-R− GCB (false discovery rate o0.01, fold change 42.3)
Signaling TRAF1, DUSP4
Cell proliferation and growth, gene expression MYC, SMAD1, STRBP, BACH2 LMO2, FAM129A, STAT3
Apoptosis ZNF385B, PEG10 FAS, BCL2A1, TMEM49
Immune response, anti-viral/ anti-microbial
activities
IGJ, DKFZp686O24166/NCR3LG1 CD58, LYZ, CHI3L1
Cell adhesion, extracellular matrix, migration BGN, CD44
MicroRNA, long noncoding RNA MIR155HG, MIR21, NCRNA00152/LINC00152
Unknown function LOC283027
2. All (GCB or ABC) MYC-R+ vs all (GCB or ABC) MYC-R− (false discovery rate o0.01, fold change 41.66)
Signaling BMP3 TNFAIP3
Cell proliferation and growth, gene expression MYC, BACH2, STRBP, SMAD1
Apoptosis PEG10, ZNF385B BCL2A1, CFLAR, TMEM49
Metabolism CYP39A1, PLA2G12A
Immune response DKFZp686O24166/NCR3LG1
Cell adhesion, extracellular matrix, migration PCDH9 CD44
MicroRNA, long noncoding RNA GAS5 MIR155HG, NCRNA00152/ LINC00152,
MIR21
Transport SLC25A27, SLC44A1, SLC35E3
Degradation RFFL
Unknown function C4orf34 LOC283027
3. MYC-R+/Mychigh DLBCL (GCB or ABC) vs MYC-R−/Mychigh DLBCL (GCB or ABC) (false discovery rate o0.01, fold change 42.05)
Signaling BMP3, BMP7
Transcription, ribosome biogenesis MYC, IKZF2, SMAD1, STRBP STAT3, BATF
Apoptosis TMEM49, CFLAR
Immune response DKFZp686O24166/NCR3LG1
Cell adhesion, extracellular matrix, migration TAPT1, PCDH9 EMILIN2, TPM4, ARHGAP25, CD44
MicroRNA, long noncoding RNA MIR21, LINC00152/NCRNA00152
Transport SLC35E3
Unknown function LOC100288765, LOC283027
Abbreviations: ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; MYC-R+, MYC rearrangement-
positive; MYC-R−, MYC rearrangement-negative; Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
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of Myc overexpression was 32.7% in overall DLBCL
patients (close to the frequencies by other indepen-
dent studies13,22,23), 73% in MYC-R+ GCB-DLBCL,
and 54% in MYC-R+ ABC-DLBCL (lower than the
93% in Green et al6 and 85% in Horn et al10).
Tables 6–7 summarize the results of published MYC
studies including ours. The current study shows that
MYC translocation and Myc overexpression in DLBCL
only partially overlaps and evaluation of both is critical
for stratifying patients and predicting treatment
outcomes. MYC-rearranged DLBCL without Myc
protein overexpression did not show significantly
worse survival (Figure 1g). However, evaluation of

















Figure 6 Prognostic analysis in Mychigh germinal-center-B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) and in MychighBcl-2high
DLBCL patients. (a and b) Among MYC-non-rearranged (MYC-R−) Mychigh GCB-DLBCL patients, those with Bcl-2 overexpression had
significantly worse overall survival and progression-free survival compared with those who did not have Bcl-2 overexpression. (c and d)
Among patients with MYC-R+/Mychigh GCB-DLBCL, those with Bcl-2 overexpression had significantly poorer progression-free survival
compared with those who did not have Bcl-2 overexpression. The P-value for overall survival was not significant. (e and f) Among patients
with MychighBcl-2high GCB-DLBCL, those with MYC rearrangement had poorer overall and progression-free survival compared with those
withoutMYC rearrangement did, but these differences were not statistically significant. (g and h) Among MychighBcl-2high DLBCL patients,
GCB-DLBCL patients with MYC rearrangement had significantly poorer overall and progression-free survival than MychighBcl-2high
patients without MYC rearrangement did. ABC, activated-B-cell-like; Bcl-2high, high Bcl-2 protein expression; Bcl-2low, low Bcl-2 protein
expression; GCB, germinal-center-B-cell-like; Mychigh, high Myc protein expression;MYC-R+,MYC rearrangement-positive;MYC-R−,MYC
rearrangement-negative.
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predicting poorer prognosis in MYC-R− cases, espe-
cially in MYC-R− GCB-DLBCL (Figure 5a). This low
specificity for Mychigh as an adverse prognostic
factor can be improved by concurrent evaluation of
Bcl-2 expression (Supplementary Figures S5 and S6),
which is overexpressed mainly in ABC-DLBCL and
associated with Myc overexpression. However, the
survival of MYC-rearranged MychighBcl-2high GCB
double-positive lymphoma patients remains signifi-
cantly worse than other double-positive lymphoma
patients (Figures 6g and h).
The biological investigation (in this regard, ≥ 70%
is a better cutoff compared with ≥40% for Mychigh in
our cohort) revealed that MYC activation was
associated with significantly increased or decreased
expression of genes and proteins involved in cell
proliferation (e.g., pAKT, Ki-67), apoptosis (p53,
Bcl-2, FAS, BCL2A1, PEG10,HINT1, TRAF1), differen-
tiation (PRDM1, BLIMP-1, BACH2 (which represses
PRDM1)43), noncoding RNAs (eg, LINC00152,
GAS5, SNHG1, NAPSB) and microRNAs, microenvi-
ronment, and immune responses, as well as cell-
of-origin markers (Figure 3 and Tables 3–5).
Corresponding to the differences in prognostic effect
between various Mychigh subtypes, only MYC-R+/
Mychigh GCB-DLBCL and MYC-R−/Mychigh ABC-
DLBCL, but not MYC-R−/Mychigh GCB-DLBCL or
MYC-R+/Mychigh ABC-DLBCL, demonstrated distinct
gene expression profiling feature compared with
the Myclow subgroup (Figures 5b and e and Supple-
mentary Figures S4D and F). Remarkably, MYC-R+/
Mychigh GCB-DLBCL had a characteristic gene expres-
sion profiling in DLBCL. Myc activation was asso-
ciated with gene expression profiling signatures
suggesting decreased immune responses and a
number of microRNAs overlapped with the mole-
cular Burkitt lymphoma signature,29,30 including
MIR17HG, which was markedly upregulated, and
MIR21 (ref. 44) and MIR155HG, which were signifi-
cantly downregulated. Other studies have shown
these microRNAs to be regulated by the Myc,
Bcl-6, STAT3, and NF-κB pathways, and theMIR17HG
locus was frequently amplified in Burkitt lym-
phoma.45–48 Downregulation ofMIR155HG expression
may contribute to the pathogenesis of MYC trans-
location, as miR-155 suppresses activation-induced
cytidine deaminase, which mediates MYC/IGH
translocation.49 These microRNA signatures may also
be implicated in defining the gene expression profiling
features of MYC-R+/Mychigh GCB-DLBCL. In lym-
phoma cells, ectopic expression of miR-155 is asso-
ciated with downregulation of IGJ, FAS, SMAD3/5,
and BACH1, as well as HLA genes.45 IGJ, FAS, and
genes involved in BMP/SMAD pathways (such as
SMAD1, BMP3, and BMP7), as well as SMARCA4
(miR-21 target gene50), were upregulated in MYC-R+
GCB-DLBCL (Tables 3 and 5). miR-155 target gene
BCL2 showed increased Bcl-2 protein expression
in ABC-DLBCL (Figure 3c). Phosphorylated SMAD
proteins have roles in BMP-induced cell growth
inhibition (this inhibition can be overcame via MYC
translocations),51,52 immunoregulation,53 and ionizing
radiation-induced double-strand break signaling.54 In
addition, in MYC-R+/Mychigh GCB-DLBCL, antiapop-
totic PEG10 and ZNF385B, which modulates p53
activity resulting in cell-cycle arrest over apoptosis,
were significantly upregulated.
One possible reason for the differential prognoses
and gene expression profiling signatures among GCB
or ABC subtype of Mychigh and MYC-R+ cases is the
difference in Myc protein levels. For example, MYC-
R+/Mychigh GCB-DLBCL had highest Myc expression
levels (Figure 2c) and significant or nonsignificant
trends towards worse prognosis compared with all
other three Mychigh groups. MYC-R+ cases with low
Myc protein expression had good prognosis even
though having an MYC rearrangement. Different
MYC translocation partners, and/or breakpoints out-
side of MYC gene leaving MYC repressor element
intact during rearrangement,4,17 may cause the low
MYC-mRNAs in these MYC-R+/Myclow DLBCL cases
(Figures 1e–g). Compared with MYC-R+/Mychigh
GCB-DLBCL, ABC subtype of MYC-R+/Mychigh
DLBCL had similar MYC-mRNA but significantly
lower Myc protein levels (Figure 2d) and trends of
better survival. MYC-R−/Mychigh GCB-DLBCL com-
pared with Myclow GCB-DLBCL had significantly
higher levels of MYC-mRNA and Myc protein, but
the false discovery rate forMYC upregulation in gene
expression profiling analysis was high (40.45),
which may suggest either Mychigh or Myclow group
are heterogeneous and the molecular mechanisms
inducing Myc in this Mychigh group include
post-transcriptional regulation. A previous Myc
study in immature and mature GCB cells during
germinal cell formation also demonstrated the lack of
correlation between Myc protein and mRNA
levels.55 The lack of distinct gene expression
profiling signatures and better survival of
MYC-R−/Mychigh GCB-DLBCL and MYC-R+/Mychigh
ABC-DLBCL compared with MYC-R+/Mychigh
GCB-DLBCL may indicate lower Myc activities
corresponding to intracellular Myc protein levels;
however, small case numbers and/or heterogeneity
among these two Mychigh DLBCL groups could also
be possible causes.
However, the Myc immunohistochemistry levels
were similar between MYC-R−/Mychigh GCB-DLBCL
and MYC-R−/Mychigh ABC-DLBCL (although GCB
type had slightly lower level of MYC-mRNA) but
their prognosis showed differences.MYC-R+/Mychigh
ABC-DLBCL had similar Myc protein level to that of
MYC-R−/Mychigh ABC-DLBCL but only the latter
showed typical Myc gene expression profiling
signatures (Figure 2c). Therefore, Myc-associated
molecular mechanisms in GCB or ABC subtype of
MYC-R+/− Mychigh cases impacted the prognostic
and biological effect of Myc. GCB and ABC subtypes
of Mychigh DLBCL had difference in frequencies of
TP53 mutation, MYC translocation, BCL2 transloca-
tion, and Bcl-2 expression, as well as cell-of-origin
biomarkers (Table 1 and Figure 3). MYC-R+/Mychigh
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and MYC-R−/Mychigh DLBCL had significantly
different levels of MDM2, the cell-of-origin markers,
and CD30 (in GCB-DLBCL) and pAKT (in
ABC-DCLBL) (Figure 4), as well as significantly
different gene expression profiling signatures at the
mRNA level (Figure 5i). Recently, studies have
posited a ‘c-Myc function rule,’ in which c-Myc is
a ‘universal amplifier’ of active (expressed) genes
in lymphocytes.33,34,57
In summary, both MYC rearrangement and Myc
overexpression have advantage and limitations as a
single biomarker in DLBCL, and their prognostic
importance is significantly different in GCB- vs
ABC-DLBCL. GCB subtype (opposite to the general
association of ABC-DLBCL with poorer survival)
of MYC-R+ DLBCL with Myc overexpression was
associated with significantly poorer survival, likely
contributed by significantly higher Myc protein
levels as well as associated tumor biology. In
ABC-DLBCL, Myc overexpression associated with
Bcl-2 overexpression was a significantly adverse
biomarker independent of MYC translocation. Our
results suggest that fluorescence in situ hybridization
analysis for MYC rearrangements and immunohis-
tochemistry evaluation for Myc and Bcl-2 expression
are both needed to determine the prognosis in
subsets of patients.57 Insights gained into the tumor
biology associated with MYC abnormalities are
important for understanding the functional role
of MYC in lymphomagenesis and chemoresistance,





frequency Significant prognostic value
van Imhoff et al.18 N=59 15% Nonsignificant trends toward inferior survival
Savage et al.12 N=137 8.8% Poorer OS and PFS
Oberman et al.14 N=220 4% Poorer survival
Tibiletti et al.19 N=74 15.8% No prognostic significance
Barrans et al.11 N=245 14% Poorer OS
Tapia et al.7 N=45 20%
Akyurek et al.56 N=239 6% Poorer OS and trend of poorer PFS (P=0.09) in GCB
Kluk et al.5 N=56 9%
Green et al.6 N=219 15%
65% of Mychigh cases
Green et al.25 N=189 11% Poorer OS
Johnson et al.22 N=290 11.7% Inferior OS and PFS when concurrent with Bcl-2high
Horn et al.13 N=407 8.8% Poorer EFS and OS
Valera et al.26 N=176 7% Poorer OS and PFS
Aukema et al.16 N=863 19.5%
Tzankov et al.15 N=432 9% Poorer disease-specific survival
Wang et al.8 N=135 24%
Horn et al.10 N=111 18%
Horn et al.27 N=103 14% Nonsignificant trend towards poorer OS (P=0.082)
Current study N=344 DLBCL 11.6% Poorer PFS
N=166 GCB 16.3% Poorer OS and PFS
N=177 ABC 7.3% No prognostic significance
N=107
N=175*
Mychigh cases 24.3% Poorer PFS
N=233
N=360*
Myclow cases 5.6% No prognostic significance
(a nonsignificant trend of better OS: P=0.25)
N=42
N=76*
Mychigh GCB 45.2% Poorer OS and PFS
N=65
N=98*
Mychigh ABC 10.8% No prognostic significance
N=60
N=98*
Mychigh/Bcl-2high DPL 23.3% GCB subtype of MYC-R+ Mychigh/Bcl-2high DPL (16.7%)
had significantly poorer OS and PFS among
Mychigh/Bcl-2high DPL
Occurrence of GCB vs ABC subtype of MYC-R+: 2.1;
Occurrence of GCB vs ABC subtype of MYC-R+/Mychigh: 2.7;
Occurrence of GCB vs ABC subtype of MYC-R+/Mychigh/Bcl-2high: 2.5
Prognosis of GCB vs ABC subtype of MYC-R+: trends towards
poorer OS and PFS (P=0.11);
Prognosis of GCB vs ABC subtype of MYC-R+/Mychigh: no significant
difference (slightly unfavorable trends);
Prognosis of GCB vs ABC subtype of MYC-R+/Mychigh/Bcl-2high:
unfavorable trends (for PFS, P=0.098)
Abbreviations: ABC, activated-B-cell like; Bcl-2high, high Bcl-2 protein expression; DLBCL, diffuse large B-cell lymphoma; DPL, double-positive
lymphoma; EFS, event-free survival; GCB, germinal center B-cell like; Mychigh, high Myc protein expression; Myclow, low Myc protein expression;
MYC-R+, MYC rearrangement positive; MYC-R¯, MYC rearrangement negative; OS, overall survival; PFS, progression-free survival.
Note: Case numbers marked by * are the total Mychigh or Myclow case numbers (with or without MYC-R status determined).
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and help identify oncogenic targets for therapeutic
intervention (Table 7).
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Table 7 Summary of frequencies and prognostic significance of Myc overexpression (Mychigh) and MYC mRNA levels in DLBCL in the






Mychigh (%) Mychigh frequency Significant prognostic value
Kluk et al.5 N=77 450 19.5% Poorer OS
Green et al.6 N=205 ≥70 17%
Green et al.25 N=193 ≥40 Poorer OS and PFS when concurrent with Bcl-2high
Johnson et al.22 N=307 ≥40 33% Inferior OS and PFS when concurrent with Bcl-2high
Hu et al.24 N=466 ≥40 64% Concurrent Mychigh/Bcl-2high correlated
with poorer OS and PFS
Horn et al.13 N=283 440 31.8% Poorer OS and PFS
Valera et al.26 N=168 10 48% Inferior OS and PFS
40 13%
Perry et al.23 N=106 450 35% Poorer OS and EFS
Horn et al.10 N=39 ≥80 77–85% of MYC-R+ cases;
19–46% of MYC-R− cases
Horn et al.27 N=92 ≥30 49% Nonsignificant trends toward poorer OS (P=0.08)
and poorer PFS (P=0.091)
Current study N=535 ≥70 32.7% Poorer OS and PFS
N=272 ≥70 27.9% in GCB Poorer OS and PFS
N=259 ≥70 37.8% in ABC Poorer OS and PFS
N=40 ≥70 67% of MYC-R+ cases Poorer OS and PFS
N=304 ≥70 26.9% of MYC-R¯ cases Poorer OS and PFS
N=26 ≥70 73% of MYC-R+ GCB Trends toward poorer OS (P=0.07) and PFS
N=136 ≥70 16.9% of MYC-R− GCB Nonsignificant trends toward poorer OS (P=0.40)
and poorer PFS (P=0.48)
N=13 ≥70 54% of MYC-R+ ABC Trends toward poorer OS and PFS (P=0.07)
N=164 ≥70 35.4% of MYC-R− ABC Poorer OS and PFS
Occurrence of ABC vs GCB subtype of Mychigh: 1.3 (in the overall DLBCL
cohort, case numbers of ABC vs GCB subtype: 0.95);
Occurrence of ABC vs GCB subtype of Mychigh/Bcl-2high: 1.8
Percentage of MYC-R−/Mychigh ABC-DLBCL among all Mychigh: 54.2%;
Percentage of MYC-R+/Mychigh GCB-DLBCL among all Mychigh: 17.8%
Prognosis of ABC vs GCB subtype of Mychigh: no significant difference (slightly
unfavorable trends);
Prognosis of ABC vs GCB subtype of Mychigh/Bcl-2high: no significant difference;
MYC-R−/Mychigh ABC vs MYC-R−/Mychigh GCB: trend of poorer OS
(for both OS and PFS: P=0.14);
MYC-R+/Mychigh ABC-DLBCL vs MYC-R−/Mychigh GCB-DLBCL: nonsignificantly
poorer OS (P=0.35) and PFS (P=0.25);
MYC-R+/Mychigh GCB-DLBCL vs MYC-R−/Mychigh ABC-DLBCL: a trend towards
poorer PFS (P=0.058)
MYC mRNA levels (3 groups: low, intermediate, and high MYC-mRNA)
References Frequency of MYC-mRNAhigh Significant prognostic value
Current study N=471 15.7% of DLBCL Poorer OS and PFS
N=241 16.6% in GCB Poorer OS and PFS
N=228 14.9% in ABC Poorer OS and a trend towards poorer PFS (P=0.069)
N=33 55% of MYC-R+ cases Poorer OS and a trend towards poorer PFS (P=0.066)
N=265 12.1% of MYC-R¯ cases Trend towards poorer OS (P=0.06)
Prognosis of ABC vs GCB subtype of MYC-mRNAhigh: no significant difference
(slightly unfavorable trends)
Abbreviations: ABC, activated B-cell like; Bcl-2high, high Bcl-2 protein expression; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival;
GCB, germinal center B-cell like; Mychigh, high Myc protein expression; Myclow, low Myc protein expression; MYC-R−, MYC rearrangement–
negative; MYC-R+, MYC rearrangement positive; OS, overall survival; PFS, progression-free survival.
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